Immatics Names Venkat Ramanan as CFO
New CFO Appointment: Immatics N.V. has appointed Venkat Ramanan, Ph.D., as Chief Financial Officer, effective immediately, succeeding Arnd Christ. Dr. Ramanan brings over 25 years of experience in the biopharmaceutical industry, having held leadership roles at companies like Seagen, Gilead Sciences, and Amgen.
Focus on PRAME Cell Therapy: Dr. Ramanan's expertise will support Immatics in advancing its PRAME cell therapy, anzu-cel, towards commercialization, particularly for patients with metastatic melanoma, as the company aims to strengthen its position as a leader in precision targeting of PRAME.
Get Free Real-Time Notifications for Any Stock
Analyst Views on IMTX
About IMTX
About the author
Immatics Sells 12.5M Shares at $10 Each, Raising $125M
- Funding Scale: Immatics has announced the sale of 12,500,000 ordinary shares at $10 each, expected to raise $125 million, which will provide crucial funding for the company's clinical development initiatives.
- Underwriter Lineup: The offering is being managed by Jefferies, Leerink Partners, and Cantor, reflecting market confidence in Immatics' future growth and potentially enhancing its reputation in the biopharmaceutical sector.
- Transaction Timeline: The offering is expected to close on December 8, 2025, subject to customary closing conditions, allowing the company to quickly access funds to support its research projects.
- Market Reaction Expectations: This financing will bolster Immatics' research capabilities in precision targeting of PRAME, potentially enhancing its competitive position in cancer treatment, particularly in therapies targeting over 50 types of cancer.
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.
Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
